CORRELATION BETWEEN THE EXPRESSION LEVEL OF NUCLEAR RECEPTOR COACTIVATOR 1 AND CLINICOPATHOLOGICAL FEATURES AND PROGNOSIS IN BLADDER CANCER

Objective: To investigate the relationship between the expression of nuclear receptor coactivator 1 (NCOA1) and clinicopathological features and prognosis of bladder cancer. Methods: 71 cases of cancer tissues and 71 cases of paracancer tissues from patients with bladder cancer who underwent surgical resection in the department of urology in our hospital from December 2012 to December 2013 were selected. The positive expression rate of NCOA1 protein in bladder cancer tissues and paracancerous tissues was detected by immunohistochemistry method. The correlation between the expression of NCOA1 protein and clinicopathological features was investigated. The relationship between the expression of NCOA1 and the patient's survival time was observed and recorded. Cox proportional risk regression model was used to analyze the independent risk factors affecting the prognosis of patients with bladder cancer. Results: NCOA1 was mainly expressed in the nucleus. The expression rate of NCOA1 in bladder cancer tissues (51/71, 71.83%) was significantly higher than that in normal paracancerous tissues (11/71, 15.49%) (P<0.05). The expression of NCOA1 protein was correlated with tumor grade, TNM stage and lymph node metastasis in patients with bladder cancer (P<0.05). The 5-year survival rate of patients with high expression of NCOA1 was 7/51(15.68%), which was significantly lower than that of patients with low expression of NCOA1 (11/20, 58.43%) (P<0.05). TNM grade, lymph node metastasis, and NCOA1 expression can be used as independent risk factors affecting prognosis of patients with bladder cancer. Conclusion: NCOA1 is highly expressed in bladder cancer, and its protein expression is associated with tumor grade, TNM stage and lymph node metastasis inpatients with bladder cancer. The higher the expression, the worse the prognosis of the patient, and it can be a new target for the treatment of bladder cancer.